Clinical Trials | May 25, 2026
AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Expands Davaindia network to 2,579 stores
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
Subscribe To Our Newsletter & Stay Updated
